Abstract Malignant mesothelioma (MM) is a treatment-resistant tumor originating in the mesothelial lining of the pleura or the abdominal cavity with very limited treatment options. More effective therapeutic approaches are urgently needed to improve the poor prognosis of MM patients. Chimeric … More
Main Navigation Menu
➤ Find Out Who Was Exposed to Asbestos and How
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Asbestos-Contaminated Talc Mesothelioma Lawsuits
➤ Mesothelioma / Lung Cancer / Asbestosis: Basic Facts
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Questions New Clients Have Asked Us (FAQs)
➤ Information About Our Law Firm
➤ Asbestos Attorney Tom Lamb
➤ Collection of News and Reports
You can use our Quick Contact Form to tell us about your case.
Recent News & Reports
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine … More
What is the link between asbestos and lung cancer?
Asbestos is a material that people have used as insulation since the Industrial Revolution. There are strong associations between asbestos and certain types of cancer, including lung cancer and mesothelioma, which is a type of cancer that affects the mesothelial cells. According to the American … More
Survival of patients with asbestosis can be assessed by risk-predicting models
Objectives: Our aim was to investigate the pulmonary function test (PFT) results of patients with asbestosis and determine whether baseline PFTs and the risk-predicting models such as gender, age and physiologic (GAP) variables model and composite physiologic index (CPI) would be useful in … More
Malignant Pleural Mesothelioma Clinical Practice Guidelines (SEOM, 2021)
Diagnosis and Staging: Genomic studies are not recommended in routine clinical practice but may be appropriate in selected patients with malignant pleural mesothelioma (MPM), especially those with young age and family history of cancer, who may carry germline mutations in cancer susceptibility … More
Study seeks to identify biological markers that predict mesothelioma response to treatment
The National Cancer Institute (NCI) has granted a $2.5 million, five-year R37 MERIT Award to Dr. Bryan Burt, associate professor of surgery and chief of the Division of General Thoracic Surgery, for his research project titled, “Proteomic Determinants of Response to Checkpoint Blockade in Malignant … More